0001140361-24-015101.txt : 20240325
0001140361-24-015101.hdr.sgml : 20240325
20240325205459
ACCESSION NUMBER: 0001140361-24-015101
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240321
FILED AS OF DATE: 20240325
DATE AS OF CHANGE: 20240325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Militello John
CENTRAL INDEX KEY: 0001662170
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 24780734
MAIL ADDRESS:
STREET 1: C/O IMMUNE PHARMACEUTICALS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0508
4
2024-03-21
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001662170
Militello John
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
See Remarks
false
Common Stock
2022-02-14
4
J
0
2903
0
A
24420
D
Common Stock
2022-04-18
4
J
0
7932
0
A
32352
D
Common Stock
2022-08-12
4
J
0
14310
0
A
46662
D
Common Stock
2023-02-14
4
J
0
11067
0
A
57729
D
Common Stock
2024-03-21
4
S
0
2490
28.104
D
55239
D
Restricted Stock Units
2022-02-14
4
J
0
2903
0
A
Common Stock
2903
0
D
Restricted Stock Units
2022-04-18
4
J
0
7932
0
A
Common Stock
7932
0
D
Restricted Stock Units
2022-08-12
4
J
0
14310
0
A
Common Stock
14310
0
D
Restricted Stock Units
2023-02-14
4
J
0
11067
0
A
Common Stock
2903
0
D
Represents Restricted Stock Units ("RSUs") that are settled in shares of common stock on a one-for-one basis upon vesting. These RSUs were initially reported on Table II and, in accordance with SEC guidance, are now being reported on Table I. This Form 4 updates the filing history of the Reporting Person to include such RSUs on Table I and does not reflect the award of new RSUs.
One-third (1/3) of such RSUs vest upon the one-year anniversary of the grant, with the remaining shares vesting in equal quarterly installments over the following two years.
Vests in full on August 12, 2025.
The shares of common stock were sold by the Reporting Person in order to pay tax obligations in connection with the vesting of RSUs over the course of 2023.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
VP, Principal Accounting Officer and Interim Principal Financial Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello
2024-03-25